

**SECTION 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING****1.1. Product identifier**

**Product Description:** ImmunoCAP Rapid QC 1  
**Cat No. :** 82-1027-01

**1.2. Relevant identified uses of the substance or mixture and uses advised against**

**Recommended Use** In vitro diagnostic  
**Uses advised against** All other uses

**1.3. Details of the supplier of the safety data sheet**

**Company** Phadia AB  
Rapsgatan 7P  
P.O. Box 6460  
751 37 UPPSALA  
Sweden  
+46 18 16 50 00  
**E-mail address** safetydatasheet.idd@thermofisher.com

**1.4. Emergency telephone number**

CHEMTREC Ireland (Dublin) +(353)-19014670  
CHEMTREC Belgium (Brussels) +(32)-28083237  
Malta 112 Emergency phone number

**SECTION 2: HAZARDS IDENTIFICATION****2.1. Classification of the substance or mixture****CLP Classification - Regulation (EC) No 1272/2008****Physical hazards**

Based on available data, the classification criteria are not met

**Health hazards**

Based on available data, the classification criteria are not met

**Environmental hazards**

Based on available data, the classification criteria are not met

*For the full text of the H-statements mentioned in this Section, see Section 16.*

**2.2. Label elements**

# SAFETY DATA SHEET

ImmunoCAP Rapid QC 1

Revision Date 02-Dec-2020

## 2.3. Other hazards

This product contains human sourced material. The donors have been tested and found to be non-reactive for HBsAg, HIV-1 Ag, anti-HCV and anti HIV-1/HIV-2.

This preparation contains no substance considered to be persistent, bioaccumulating nor toxic (PBT). This preparation contains no substance considered to be very persistent nor very bioaccumulating (vPvB).

## SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

### 3.1. Substances

### 3.2. Mixtures

Component	CAS-No	EC-No.	Weight %	CLP Classification - Regulation (EC) No 1272/2008
Pooled human sera	-		>99	-
Sodium azide	26628-22-8	EEC No. 247-852-1	<0.1	Acute Tox. 2 (H300) (EUH032) Aquatic Acute 1 (H400) Aquatic Chronic 1 (H410)

Component	Specific concentration limits (SCL's)	M-Factor	Component notes
Sodium azide	-	1	-

For the full text of the H-statements mentioned in this Section, see Section 16.

## SECTION 4: FIRST AID MEASURES

### 4.1. Description of first aid measures

Eye Contact	Rinse thoroughly with plenty of water, also under the eyelids.
Skin Contact	Wash off immediately with soap and plenty of water.
Ingestion	Rinse mouth. If possible drink milk afterwards.
Inhalation	Not applicable.
Self-Protection of the First Aider	Ensure that medical personnel are aware of the material(s) involved, take precautions to protect themselves and prevent spread of contamination.

### 4.2. Most important symptoms and effects, both acute and delayed

No information available.

### 4.3. Indication of any immediate medical attention and special treatment needed

# SAFETY DATA SHEET

ImmunoCAP Rapid QC 1

Revision Date 02-Dec-2020

## Notes to Physician

Treat symptomatically.

## SECTION 5: FIREFIGHTING MEASURES

### 5.1. Extinguishing media

#### **Suitable Extinguishing Media**

Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

#### **Extinguishing media which must not be used for safety reasons**

None known.

### 5.2. Special hazards arising from the substance or mixture

None known.

#### **Hazardous Combustion Products**

None known.

### 5.3. Advice for firefighters

As in any fire, wear self-contained breathing apparatus pressure-demand, MSHA/NIOSH (approved or equivalent) and full protective gear.

## SECTION 6: ACCIDENTAL RELEASE MEASURES

### 6.1. Personal precautions, protective equipment and emergency procedures

Wear protective gloves/clothing and eye/face protection.

### 6.2. Environmental precautions

Dispose of in accordance with local regulations.

### 6.3. Methods and material for containment and cleaning up

Wipe up with adsorbent material (e.g. cloth, fleece). Dispose of waste product or used containers according to local regulations.

### 6.4. Reference to other sections

Refer to protective measures listed in Sections 8 and 13.

## SECTION 7: HANDLING AND STORAGE

### 7.1. Precautions for safe handling

Wash thoroughly after handling. Do not eat, drink or smoke when using this product.

### 7.2. Conditions for safe storage, including any incompatibilities

Observe instructions for use.

### 7.3. Specific end use(s)

Observe instructions for use.

# SAFETY DATA SHEET

ImmunoCAP Rapid QC 1

Revision Date 02-Dec-2020

## SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

### 8.1. Control parameters

#### Exposure limits

Component	European Union	The United Kingdom	France	Belgium	Spain
Sodium azide	TWA: 0.1 mg/m <sup>3</sup> (8h) STEL: 0.3 mg/m <sup>3</sup> (15min) Skin	STEL: 0.3 mg/m <sup>3</sup> 15 min TWA: 0.1 mg/m <sup>3</sup> 8 hr Skin	TWA / VME: 0.1 mg/m <sup>3</sup> (8 heures). restrictive limit STEL / VLCT: 0.3 mg/m <sup>3</sup> . restrictive limit Peau	Huid	STEL / VLA-EC: 0.3 mg/m <sup>3</sup> (15 minutos). TWA / VLA-ED: 0.1 mg/m <sup>3</sup> (8 horas) Piel

Component	Italy	Germany	Portugal	The Netherlands	Finland
Sodium azide	TWA: 0.1 mg/m <sup>3</sup> 8 ore. Media Ponderata nel Tempo STEL: 0.3 mg/m <sup>3</sup> 15 minuti. Breve termine Pelle	TWA: 0.2 mg/m <sup>3</sup> (8 Stunden). AGW - exposure factor 2 TWA: 0.2 mg/m <sup>3</sup> (8 Stunden). MAK Höhepunkt: 0.4 mg/m <sup>3</sup>	STEL: 0.3 mg/m <sup>3</sup> 15 minutos Ceiling: 0.29 mg/m <sup>3</sup> Ceiling: 0.11 ppm TWA: 0.1 mg/m <sup>3</sup> 8 horas Pele	huid STEL: 0.3 mg/m <sup>3</sup> 15 minuten TWA: 0.1 mg/m <sup>3</sup> 8 uren	TWA: 0.1 mg/m <sup>3</sup> 8 tunteina STEL: 0.3 mg/m <sup>3</sup> 15 minuutteina Iho

Component	Austria	Denmark	Switzerland	Poland	Norway
Sodium azide	Haut MAK-KZW: 0.3 mg/m <sup>3</sup> 15 Minuten MAK-TMW: 0.1 mg/m <sup>3</sup> 8 Stunden	TWA: 0.1 mg/m <sup>3</sup> 8 timer Hud	STEL: 0.4 mg/m <sup>3</sup> 15 Minuten TWA: 0.2 mg/m <sup>3</sup> 8 Stunden	STEL: 0.3 mg/m <sup>3</sup> 15 minutach TWA: 0.1 mg/m <sup>3</sup> 8 godzinach	TWA: 0.1 mg/m <sup>3</sup> 8 timer STEL: 0.3 mg/m <sup>3</sup> 15 minutter. value from the regulation

Component	Bulgaria	Croatia	Ireland	Cyprus	Czech Republic
Sodium azide	TWA: 0.1 mg/m <sup>3</sup> STEL : 0.3 mg/m <sup>3</sup> Skin notation	kože TWA-GVI: 0.1 mg/m <sup>3</sup> 8 satima. STEL-KGVI: 0.3 mg/m <sup>3</sup> 15 minutama.	TWA: 0.1 mg/m <sup>3</sup> 8 hr. STEL: 0.3 mg/m <sup>3</sup> 15 min Skin	Skin-potential for cutaneous absorption STEL: 0.3 mg/m <sup>3</sup> TWA: 0.1 mg/m <sup>3</sup>	TWA: 0.1 mg/m <sup>3</sup> 8 hodinách. Potential for cutaneous absorption Ceiling: 0.3 mg/m <sup>3</sup>

Component	Estonia	Gibraltar	Greece	Hungary	Iceland
Sodium azide	Nahk TWA: 0.1 mg/m <sup>3</sup> 8 tundides. STEL: 0.3 mg/m <sup>3</sup> 15 minutites.	Skin notation TWA: 0.1 mg/m <sup>3</sup> 8 hr STEL: 0.3 mg/m <sup>3</sup> 15 min	STEL: 0.1 ppm STEL: 0.3 mg/m <sup>3</sup> TWA: 0.1 ppm TWA: 0.3 mg/m <sup>3</sup>	STEL: 0.3 mg/m <sup>3</sup> 15 percekben. CK TWA: 0.1 mg/m <sup>3</sup> 8 óraban. AK	STEL: 0.3 mg/m <sup>3</sup> TWA: 0.1 mg/m <sup>3</sup> 8 klukkustundum. Skin notation

Component	Latvia	Lithuania	Luxembourg	Malta	Romania
Sodium azide	skin - potential for cutaneous exposure STEL: 0.3 mg/m <sup>3</sup> TWA: 0.1 mg/m <sup>3</sup>	TWA: 0.1 mg/m <sup>3</sup> IPRD Oda STEL: 0.3 mg/m <sup>3</sup>	Possibility of significant uptake through the skin TWA: 0.1 mg/m <sup>3</sup> 8 Stunden STEL: 0.3 mg/m <sup>3</sup> 15 Minuten	possibility of significant uptake through the skin TWA: 0.1 mg/m <sup>3</sup> STEL: 0.3 mg/m <sup>3</sup> 15 minuti	Skin notation TWA: 0.1 mg/m <sup>3</sup> 8 ore STEL: 0.3 mg/m <sup>3</sup> 15 minute

Component	Russia	Slovak Republic	Slovenia	Sweden	Turkey
Sodium azide		Ceiling: 0.3 mg/m <sup>3</sup> Potential for cutaneous absorption TWA: 0.1 mg/m <sup>3</sup>	TWA: 0.1 mg/m <sup>3</sup> 8 urah Koža STEL: 0.3 mg/m <sup>3</sup> 15 minutah	Binding STEL: 0.3 mg/m <sup>3</sup> 15 minuter TLV: 0.1 mg/m <sup>3</sup> 8 timmar. NGV	Deri TWA: 0.1 mg/m <sup>3</sup> 8 saat STEL: 0.3 mg/m <sup>3</sup> 15 dakika

#### Biological limit values

This product, as supplied, does not contain any hazardous materials with biological limits established by the region specific regulatory bodies

# SAFETY DATA SHEET

ImmunoCAP Rapid QC 1

Revision Date 02-Dec-2020

## Monitoring methods

BS EN 14042:2003 Title Identifier: Workplace atmospheres. Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents.

**Derived No Effect Level (DNEL)** No information available.

**Predicted No Effect Concentration (PNEC)** No information available.

## 8.2. Exposure controls

### Engineering Measures

None under normal use conditions.

### Personal protective equipment

**Eye Protection** No special protective equipment required.

**Hand Protection** Protective gloves.

Glove material	Breakthrough time	Glove thickness	EU standard	Glove comments
Nitrile rubber	See manufacturers recommendations	-	EN 374	(minimum requirement)

**Skin and body protection** No special protective equipment required.

**Respiratory Protection** No protective equipment is needed under normal use conditions.

**Large scale/emergency use** No protective equipment is needed under normal use conditions

**Small scale/Laboratory use** No personal respiratory protective equipment normally required.

**Hygiene Measures** Handle in accordance with good industrial hygiene and safety practice.

**Environmental exposure controls** Dispose of contents/containers in accordance with local regulations.

## SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

### 9.1. Information on basic physical and chemical properties

**Physical State** Liquid

**Appearance** Yellow

**Odor** None

**Odor Threshold** None

**Melting Point/Range** No data available

**Softening Point** No data available

**Boiling Point/Range** No data available

**Flammability (liquid)** No data available

**Flammability (solid,gas)** Not flammable

**Explosion Limits** Not applicable

**Flash Point** Not applicable

**Method -** No information available

**Autoignition Temperature** Not applicable

**Decomposition Temperature** Not applicable

**pH** No data available

**Viscosity** No data available

# SAFETY DATA SHEET

ImmunoCAP Rapid QC 1

Revision Date 02-Dec-2020

Water Solubility	Soluble in water
Solubility in other solvents	No information available
Partition Coefficient (n-octanol/water)	
Component	log Pow
Sodium azide	0.3
Vapor Pressure	No data available
Density / Specific Gravity	No data available
Bulk Density	No data available
Vapor Density	No data available (Air = 1.0)
Particle characteristics	Not applicable (liquid)

## 9.2. Other information

Explosive Properties	Not applicable
Oxidizing Properties	Not applicable

## SECTION 10: STABILITY AND REACTIVITY

### 10.1. Reactivity

None known.

### 10.2. Chemical stability

Stable under normal conditions.

### 10.3. Possibility of hazardous reactions

Hazardous Polymerization	Hazardous polymerization does not occur.
Hazardous Reactions	None under normal processing.

### 10.4. Conditions to avoid

None known.

### 10.5. Incompatible materials

None known.

### 10.6. Hazardous decomposition products

None known.

## SECTION 11: TOXICOLOGICAL INFORMATION

### 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

Product Information	Product does not present an acute toxicity hazard based on known or supplied information.
---------------------	---

#### (a) acute toxicity;

Oral	No data available.
Dermal	No data available.
Inhalation	No data available.

#### Toxicology data for the components

Component	LD50 Oral	LD50 Dermal	LC50 Inhalation
Sodium azide	LD50 = 27 mg/kg ( Rat )	20 mg/kg ( Rabbit )	37 mg/l ( Rat )

(b) skin corrosion/irritation;	No data available.
--------------------------------	--------------------

(c) serious eye damage/irritation;

# SAFETY DATA SHEET

ImmunoCAP Rapid QC 1

Revision Date 02-Dec-2020

**(d) respiratory or skin sensitization;**

Respiratory No data available.  
Skin No data available.

**(e) germ cell mutagenicity;** No data available.

**(f) carcinogenicity;** There are no known carcinogenic chemicals in this product.

Component	Test method	Test species / Duration	Study result
Sodium azide			No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**(g) reproductive toxicity;** No data available.

**(h) STOT-single exposure;** No data available.

**(i) STOT-repeated exposure;** No data available.

**(j) aspiration hazard;** No data available.

Component	Other Adverse Effects
Sodium azide	Symptoms of overexposure are dizziness, headache, tiredness, nausea, unconsciousness, cessation of breathing. Harmful to central nervous system and heart. Fatal if swallowed.

**Symptoms / effects, both acute and delayed** No information available.

## 11.2. Information on other hazards

**Endocrine Disrupting Properties** This product does not contain any known or suspected endocrine disruptors.

## SECTION 12: ECOLOGICAL INFORMATION

### 12.1. Toxicity

**Ecotoxicity effects** No information available.

Component	Freshwater Fish	Water Flea	Freshwater Algae	Microtox
Sodium azide	LC50 96 h 0.7 mg/L LC50 96 h LC50 0.7 mg/l 96 H (Lepomis macrochirus)	EC50 4.2 mg/l 48 h (Daphnia pulex)	IC50 272 mg/l (green algae)	EC50 38.5 mg/l (Photobacterium phosphoreum)

**12.2. Persistence and degradability** No information available.

**12.3. Bioaccumulative potential** No information available.

Component	log Pow	Bioconcentration factor (BCF)
Sodium azide	0.3	

# SAFETY DATA SHEET

ImmunoCAP Rapid QC 1

Revision Date 02-Dec-2020

<b>12.4. Mobility in soil</b>	No information available.
<b>12.5. Results of PBT and vPvB assessment</b>	This preparation contains no substance considered to be persistent, bioaccumulating nor toxic (PBT). This preparation contains no substance considered to be very persistent nor very bioaccumulating (vPvB).
<b>12.6. Endocrine disrupting properties</b> <b>Endocrine Disruptor Information</b>	No information available This product does not contain any known or suspected endocrine disruptors
<b>12.7. Other adverse effects</b> <b>Persistent Organic Pollutant</b> <b>Ozone Depletion Potential</b>	No known effect. No known effect.

## SECTION 13: DISPOSAL CONSIDERATIONS

<b>13.1. Waste treatment methods</b>	
<b>Waste from Residues/Unused Products</b>	Dispose of in accordance with local regulations.
<b>Contaminated Packaging</b>	Dispose of in accordance with local regulations.
<b>European Waste Catalogue (EWC)</b> <b>Other Information</b>	18 01 07 Chemicals other than those mentioned in 18 01 06. No information available.

## SECTION 14: TRANSPORT INFORMATION

<b>IMDG/IMO</b>	Not regulated
<b>14.1. UN number</b> <b>14.2. UN proper shipping name</b> <b>14.3. Transport hazard class(es)</b> <b>14.4. Packing group</b>	
<b>ADR</b>	Not regulated
<b>14.1. UN number</b> <b>14.2. UN proper shipping name</b> <b>14.3. Transport hazard class(es)</b> <b>14.4. Packing group</b>	
<b>IATA</b>	Not regulated
<b>14.1. UN number</b> <b>14.2. UN proper shipping name</b> <b>14.3. Transport hazard class(es)</b> <b>14.4. Packing group</b>	
<b>14.5. Environmental hazards</b>	No hazards identified.
<b>14.6. Special precautions for user</b>	No special precautions required.
<b>14.7. Maritime transport in bulk according to IMO instruments</b>	Not applicable, packaged goods.



# SAFETY DATA SHEET

ImmunoCAP Rapid QC 1

Revision Date 02-Dec-2020

## SECTION 15: REGULATORY INFORMATION

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

#### International Inventories

X = listed

Component	EINECS	ELINCS	NLP	TSCA	DSL	NDSL	PICCS	ENCS	IECSC	AICS	KECL
Sodium azide	247-852-1	-		X	X	-	X	X	X	X	KE-3135 7

### Regulation (EC) No 649/2012 of the European Parliament and of the Council of 4 July 2012 concerning the export and import of dangerous chemicals

Not applicable

#### National Regulations

Component	Germany - Water Classification (VwVwS)	Germany - TA-Luft Class
Sodium azide	WGK2	

**UK** - Take note of Control of Substances Hazardous to Health Regulations (COSHH) 2002 and 2005 Amendment.

### 15.2. Chemical safety assessment

A Chemical Safety Assessment/Report (CSA/CSR) is not required.

## SECTION 16: OTHER INFORMATION

### Full text of H-Statements referred to under sections 2 and 3

H300 - Fatal if swallowed

H400 - Very toxic to aquatic life

H410 - Very toxic to aquatic life with long lasting effects

EUH032 - Contact with acids liberates very toxic gas

### Legend

**CAS** - Chemical Abstracts Service

**EINECS/ELINCS** - European Inventory of Existing Commercial Chemical Substances/EU List of Notified Chemical Substances

**PICCS** - Philippines Inventory of Chemicals and Chemical Substances

**IECSC** - Chinese Inventory of Existing Chemical Substances

**KECL** - Korean Existing and Evaluated Chemical Substances

**TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory

**DSL/NDSL** - Canadian Domestic Substances List/Non-Domestic Substances List

**ENCS** - Japanese Existing and New Chemical Substances

**AICS** - Australian Inventory of Chemical Substances

**NZIoC** - New Zealand Inventory of Chemicals

**WEL** - Workplace Exposure Limit

**ACGIH** - American Conference of Governmental Industrial Hygienists

**DNEL** - Derived No Effect Level

**RPE** - Respiratory Protective Equipment

**LC50** - Lethal Concentration 50%

**NOEC** - No Observed Effect Concentration

**PBT** - Persistent, Bioaccumulative, Toxic

**TWA** - Time Weighted Average

**IARC** - International Agency for Research on Cancer  
Predicted No Effect Concentration (PNEC)

**LD50** - Lethal Dose 50%

**EC50** - Effective Concentration 50%

**POW** - Partition coefficient Octanol:Water

**vPvB** - very Persistent, very Bioaccumulative

**ADR** - European Agreement Concerning the International Carriage of Dangerous Goods by Road

**IMO/IMDG** - International Maritime Organization/International Maritime Dangerous Goods Code

**OECD** - Organisation for Economic Co-operation and Development

**BCF** - Bioconcentration factor

**Key literature references and sources for data**

**ICAO/IATA** - International Civil Aviation Organization/International Air Transport Association

**MARPOL** - International Convention for the Prevention of Pollution from Ships

**ATE** - Acute Toxicity Estimate

**VOC** (volatile organic compound)

# SAFETY DATA SHEET

ImmunoCAP Rapid QC 1

Revision Date 02-Dec-2020

<https://echa.europa.eu/information-on-chemicals>  
Suppliers safety data sheet, Chemadvisor - LOLI, Merck index, RTECS

<b>Physical hazards</b>	On basis of test data
<b>Health Hazards</b>	Calculation method
<b>Environmental hazards</b>	Calculation method

## Training Advice

Chemical hazard awareness training, incorporating labelling, Safety Data Sheets (SDS), Personal Protective Equipment (PPE) and hygiene.

<b>Revision Date</b>	02-Dec-2020
<b>Revision Summary</b>	Update to CLP Format, SDS sections updated, 1, 3, 16.

**This safety data sheet complies with the requirements of Regulation (EC) No. 1907/2006  
COMMISSION REGULATION (EU) 2020/878 amending Annex II to Regulation (EC) No  
1907/2006**

## Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text

**End of Safety Data Sheet**